Your browser doesn't support javascript.
loading
CRISPR/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy.
Giuffrida, Lauren; Sek, Kevin; Henderson, Melissa A; Lai, Junyun; Chen, Amanda X Y; Meyran, Deborah; Todd, Kirsten L; Petley, Emma V; Mardiana, Sherly; Mølck, Christina; Stewart, Gregory D; Solomon, Benjamin J; Parish, Ian A; Neeson, Paul J; Harrison, Simon J; Kats, Lev M; House, Imran G; Darcy, Phillip K; Beavis, Paul A.
Afiliación
  • Giuffrida L; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Vic, Australia.
  • Sek K; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Vic, Australia.
  • Henderson MA; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Vic, Australia.
  • Lai J; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Vic, Australia.
  • Chen AXY; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Vic, Australia.
  • Meyran D; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Vic, Australia.
  • Todd KL; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Vic, Australia.
  • Petley EV; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Vic, Australia.
  • Mardiana S; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Vic, Australia.
  • Mølck C; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Vic, Australia.
  • Stewart GD; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Vic, Australia.
  • Solomon BJ; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Vic, Australia.
  • Parish IA; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Vic, Australia.
  • Neeson PJ; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Vic, Australia.
  • Harrison SJ; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Vic, Australia.
  • Kats LM; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Vic, Australia.
  • House IG; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Vic, Australia.
  • Darcy PK; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Vic, Australia.
  • Beavis PA; Department of Pathology, University of Melbourne, Parkville, Vic, Australia.
Nat Commun ; 12(1): 3236, 2021 05 28.
Article en En | MEDLINE | ID: mdl-34050151
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Linfocitos T / Inmunoterapia Adoptiva / Receptor de Adenosina A2A / Neoplasias Tipo de estudio: Prognostic_studies Idioma: En Revista: Nat Commun Asunto de la revista: BIOLOGIA / CIENCIA Año: 2021 Tipo del documento: Article País de afiliación: Australia
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Linfocitos T / Inmunoterapia Adoptiva / Receptor de Adenosina A2A / Neoplasias Tipo de estudio: Prognostic_studies Idioma: En Revista: Nat Commun Asunto de la revista: BIOLOGIA / CIENCIA Año: 2021 Tipo del documento: Article País de afiliación: Australia